budesonide; formoterol fumarate - Profile

What are the generic drug sources for budesonide; formoterol fumarate and what is the scope of patent protection?

Budesonide; formoterol fumarate is the generic ingredient in four branded drugs marketed by Astrazeneca, Mylan, and Astrazeneca Ab, and is included in four NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Budesonide; formoterol fumarate has one hundred and ninety-two patent family members in thirty-two countries.

Summary for budesonide; formoterol fumarate

International Patents:	192
US Patents:	9
Tradenames:	4
Applicants:	3
NDAs:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for budesonide; formoterol fumarate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for budesonide; formoterol fumarate

Constraining patent/regulatory exclusivity:

10,716,753

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for budesonide; formoterol fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes	10,716,753		Y
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes	9,415,009
Mylan	BREYNA	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	211699-001	Mar 15, 2022	AB	RX	No	No
Mylan	BREYNA	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	211699-002	Mar 15, 2022	AB	RX	No	No
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-001	Jul 21, 2006	AB	RX	Yes	Yes
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-002	Jul 21, 2006	AB	RX	Yes	Yes

International Patents for budesonide; formoterol fumarate

Country	Patent Number	Title	Estimated Expiration
Lithuania	2435025
Hungary	E031283
Taiwan	201109049	Compositions for respiratory delivery of active agents and associated methods and systems
Australia	2010253950
Russian Federation	2586297
Russian Federation	2016117972

Supplementary Protection Certificates for budesonide; formoterol fumarate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435025	CR 2019 00032	Denmark		PRODUCT NAME: KOMBINATION AF GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERER ELLER SOLVATER DERAF, OG FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERE ELLER SOLVATER DERAF; REG. NO/DATE: EU/1/18/1339 20181220
2435025	2019026	Norway		PRODUCT NAME: KOMBINASJON AV GLYKOPYRROLAT (INKLUDERT EVENTUELLE FARMASOEYTISK AKSEPTABLE SALTER, ESTERE ELLER ENANTIOMERER DERAV) OG FORMOTEROL (INNBEFATTENDE HVILKE SOM HELST FARMASOEYTISK AKSEPTABLE SALTER, ESTERE ELLER ENANTIOMERER DERAV); REG. NO/DATE: EU/1/18/1339 20190104
2435024	LUC00208	Luxembourg		PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
2435024	C02435024/01	Switzerland		PRODUCT NAME: BUDESONID, GLYCOPYRRONIUM UND FORMOTEROL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68388 24.11.2021
2435025	132019000000087	Italy		PRODUCT NAME: UNA COMBINAZIONE DI GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, ENANTIOMERI O ALTRI DERIVATI FARMACEUTICAMENTE ACCETTABILI) E FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, ENANTIOMERI O ALTRI DERIVATI FARMACEUTICAMENTE ACCETTABILI)(BEVESPI AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1339, 20181220
2435025	C201930043	Spain		PRODUCT NAME: UNA COMBINACION DE GLICOPIRROLATO (INCLUYENDO CUALQUIERA DE SUS SALES, ESTERES O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES) Y FORMOTEROL (INCLUYENDO CUALQUIERA DE SUS SALES, ESTERES O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES).; NATIONAL AUTHORISATION NUMBER: EU/1/18/1339; DATE OF AUTHORISATION: 20181218; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1339; DATE OF FIRST AUTHORISATION IN EEA: 20181218

Budesonide and Formoterol Fumarate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

This analysis evaluates the investment potential, market landscape, and financial outlook for the combination drug budesonide and formoterol fumarate. The combination therapy is primarily marketed for asthma and Chronic Obstructive Pulmonary Disease (COPD). Market growth is driven by rising respiratory disease prevalence, evolving treatment guidelines, and expanding global healthcare access. The drug’s projected revenue, competitive environment, regulatory landscape, and patent considerations inform its investment viability.

---

Introduction

Budesonide and formoterol fumarate is a combination inhaler prescribed for maintenance therapy of asthma and COPD, approved by regulatory agencies worldwide. Its market positioning hinges on efficacy, safety profile, patent protections, and strategic partnerships. Understanding the market dynamics and financial trajectory is essential for investors and corporate strategists.

---

1. Pharmaceutical Profile and Market Overview

1.1 Drug Composition and Indications

Component	Type	Approved Uses	Delivery Method	Pharmacological Class
Budesonide	Corticosteroid	Asthma, COPD maintenance	Inhaler (MDI, DPI)	Anti-inflammatory
Formoterol Fumarate	Long-acting Beta-2 Agonist	Asthma, COPD maintenance	Inhaler (MDI, DPI)	Bronchodilator

Marketed under brand names such as Symbicort (AstraZeneca), it accounts for a substantial share in respiratory therapy.

1.2 Market Size and Forecast (2023–2030)

Metric	Value (USD Billion)	CAGR (2023–2030)	Source
Global respiratory inhalers	$15.5	4.3%	Research, MarketWatch[1]
Budesonide/Formoterol Market	$4.2	5.2%	Grand View Research[2]

• Key Drivers:
  • Rising COPD and asthma prevalence: >300 million COPD cases and 262 million asthma cases globally (WHO, 2021).
  • Aging populations in North America, Europe, and Asia-Pacific.
  • Greater diagnosis rates and treatment adoption.

---

2. Investment Scenario in the Context of Market Dynamics

2.1 Competitive Landscape

Competitors	Key Features	Market Share (%)	Notable Drugs	Patent Status
AstraZeneca's Symbicort	Leading global inhaler, strong brand	55%	Symbicort	Expired in 2020 (US), ongoing patents worldwide
GlaxoSmithKline (Relvar/Breteugy)	Competitive inhaler, high efficacy	20%	Relvar/Breteugy	Patents until 2024–2025
Teva / Mylan	Generic and biosimilar options	10%	Various generics	Patent expirations increasing
Others	Niche players	15%	Multiple regional brands	Mostly generic status

2.2 Patent and Regulatory Landscape

Aspect	Details	Implication
Patent Expiry (USA)	Symbicort patent expired in 2020	Increased biosimilar competition
Regulatory Approvals (Major Markets)	EMA, FDA, PMDA approve for COPD/asthma; recent approvals in China, India	Expanding market access
Orphan/Innovation Designations	Limited; blockbuster status limits post-patent exclusivity	Competitive pressure increases

2.3 Market Entry Barriers and Opportunities

Barriers	Opportunities	Strategic Considerations
Patent expirations, generics rise	Launch of next-generation delivery systems	Innovation and patent extensions
Regulatory hurdles	Growing demand in emerging markets	Market localization strategies
High R&D costs	Potential for biosimilar and bioconjugate development	Partnerships and licensing

---

3. Financial Trajectory and Revenue Projections

3.1 Revenue Estimation and Growth Drivers

Year	Estimated Global Revenue (USD Billion)	Key Factors	Source/Assumptions
2023	$4.2	Current market size, steady adoption	Grand View Research[2]
2025	$5.4	Increased adoption, emerging markets	+6–8% CAGR estimated
2030	$8.5	Market growth, patent strategies, pipeline	5.2% CAGR over 2023–2030

3.2 Revenue Breakdown by Region

Region	Share of Total Revenue (%)	Growth Rate (%)	Notes
North America	45%	4.0%	Mature, high adoption, patent expiry concerns
Europe	25%	3.8%	Slight growth, patent cliff ahead
Asia-Pacific	20%	6.0%	Rapid growth, expanding healthcare infrastructure
Rest of World	10%	5.5%	Entry-stage, licensing opportunities

3.3 Cost and Profitability Considerations

Cost Component	Approximate Share (%)	Notes
R&D	10–15% of revenues	Pipeline development, biosimilar R&D
Manufacturing	20–25%	Scale-up, regional manufacturing costs
Marketing & Distribution	30–35%	Market penetration, brand maintenance
Regulatory & Compliance	5–10%	Regulatory filings, post-approval studies

Profit margins are heavily influenced by patent protections and generic competition; branded drugs typically achieve 20–30% net margins.

---

4. Comparative Analysis

Parameter	Budesonide/Formoterol Combination	Alternative Therapies
Market Penetration	High in developed regions	Variable, dependent on regional access
Patent Status	Expired or expiring in key markets	Varies – newer formulations patent protected
Cost to Patients	Moderate–high	Cheaper generics in some regions
Innovation Pipeline	Moderate (new devices/delivery systems)	Varies, with some generic competitors
Regulatory Challenges	Managed, with ongoing approvals	Varying degrees depending on region

---

5. Future Outlook and Strategic Inferences

5.1 Opportunities

• Expansion into emerging markets with unmet needs.
• Development of fixed-dose combinations with other therapeutic agents.
• Adoption of digital health solutions for inhaler monitoring.
• Biosimilar and bioconjugate development post-patent expiry.

5.2 Risks

• Accelerated generic entry post-patent expiry impacts revenues.
• Regulatory delays or unfavorable safety data.
• Competition from novel therapeutics or biologics.
• Pricing pressures under evolving healthcare reimbursement models.

---

6. Key Investment Considerations

Aspect	Evaluation	Actionable Insights
Patent Landscape	Patent expirations could thin margins; innovation as a counter	Invest early before biosimilar entries, or focus on pipeline assets
Market Penetration	Growth driven by emerging markets and improved access	Leverage regional partnerships, local manufacturing, and registration strategies
Competitive Differentiation	Innovation in delivery devices and formulations	Invest in R&D for next-generation inhalers
Regulatory Environment	Faster approvals in key markets present opportunities	Monitor local policies, build regulatory expertise

---

7. Comparative Financial Metrics

Metric	Symbicort (AstraZeneca)	Relvar (GSK)	Market Average
Estimated 2022 Revenue (USD billion)	$3.6	$1.4	--
Operating Margin	~25%	~23%	20–30%
R&D Investment (as % of revenue)	12%	13%	10–15%
Patent Expiry Year	2020 (some markets)	2025	Various, increasing competition likelihood

---

8. Regulatory and Policy Environment

• FDA and EMA: Approve and regulate inhalers; post-market surveillance critical.
• Pricing and Reimbursement: Price controls and reimbursement policies increasingly impacting profitability.
• Global Access Policies: WHO initiatives support increased access, especially in LMICs.
• Patent Law and Exclusivity: Patent protections typically last 20 years; extensions and data exclusivities vary.

---

9. Conclusion: Investment Outlook

The budesonide and formoterol fumarate combination remains a prominent respiratory therapy with robust market potential. While patent expirations introduce revenue pressures, opportunities in emerging markets and pipeline development offer avenues for growth. Investors should focus on:

• Patents and exclusivity windows.
• Pipeline innovation, including delivery systems.
• Expansion into emerging markets.
• Competitive landscape evolution.

---

10. Key Takeaways

• The global respiratory inhaler market is projected to reach $15.5 billion by 2030, with a CAGR of ~4.3%.
• The combination drug's revenue is expected to grow at approximately 5.2% annually from 2023 to 2030.
• Patent expirations in developed markets necessitate focus on pipeline assets and biosimilars.
• Emerging markets present significant growth opportunities, especially with improved healthcare infrastructure.
• Strategic collaborations and innovation in delivery devices can extend product life cycle and market share.

---

FAQs

Q1: What are the main competitors to budesonide/formoterol inhalers?
A1: The primary competitors include GlaxoSmithKline’s Relvar/Breteugy, Teva’s generic formulations, and other combination inhalers like Advair (fluticasone/salmeterol).

Q2: How do patent expirations affect the financial trajectory of this drug?
A2: Patent expiries usually lead to generic competition, significantly reducing revenue margins from branded formulations. This necessitates early pipeline development and strategic planning.

Q3: Which geographical markets show the highest growth potential?
A3: Asia-Pacific and Latin America exhibit high growth potential due to expanding healthcare access, rising prevalence of respiratory diseases, and increasing affordability.

Q4: What regulatory challenges could impact this drug's market?
A4: Regulatory delays, safety concerns, and differing approval processes across regions may hinder timely market access or product launches.

Q5: How can companies extend the market life of budesonide/formoterol products?
A5: Through innovation in drug delivery devices, formulation improvements, combination therapy with novel agents, and entering emerging markets early.

---

References

[1] MarketWatch. Global Inhaler Market Size, Share & Trends Analysis Report, 2023–2030.
[2] Grand View Research. Respiratory Drugs Market Size, Share & Trends Analysis, 2023–2030.